Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: Preclinical characterization of INCB028050

Journal of Immunology

Volumn 184, Issue 9, 2010, Pages 5298-5307

  Fridman, Jordan S ^a   Scherle, Peggy A ^a   Collins, Robert ^a   Burn, Timothy C ^a   Li, Yanlong ^a   Li, Jun ^a   Covington, Maryanne B ^a   Thomas, Beth ^a   Collier, Paul ^a   Favata, Margaret F ^a   Wen, Xiaoming ^a   Shi, Jack ^a   McGee, Ryan ^a   Haley, Patrick J ^a   Shepard, Stacey ^a   Rodgers, James D ^a   Yeleswaram, Swamy ^a   Hollis, Greg ^a   Newton, Robert C ^a   Metcalf, Brian ^a   Friedman, Steven M ^a   Vaddi, Kris ^a   more..

^a Experimental Station   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INCB 028050; INTERLEUKIN 23; INTERLEUKIN 6; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE INHIBITOR; UNCLASSIFIED DRUG; AUTACOID; JAK1 PROTEIN, RAT; JAK2 PROTEIN, RAT; PROTEIN KINASE INHIBITOR;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOLOGY; INTRACELLULAR SIGNALING; MALE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS; TH1 CELL; TH17 CELL; ANIMAL; ARTHRITIS; AUTOIMMUNE DISEASE; BAGG ALBINO MOUSE; CELL LINE; CHEMISTRY; DBA MOUSE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; IMMUNOLOGY; LEWIS RAT; METHODOLOGY; MOUSE; PHYSIOLOGY; RANDOMIZATION; SIGNAL TRANSDUCTION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; AUTOIMMUNE DISEASES; CELL LINE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; INFLAMMATION MEDIATORS; JANUS KINASE 1; JANUS KINASE 2; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; PROTEIN KINASE INHIBITORS; RANDOM ALLOCATION; RATS; RATS, INBRED LEW; SIGNAL TRANSDUCTION;

EID: 77954531991     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902819     Document Type: Article

References (34)

1. McInnes, I. B., and F. Y. Liew. 2005. Cytokine networks - towards new therapies for rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 1: 31-39.
2. Smolen, J. S., A. Beaulieu, A. Rubbert-Roth, C. Ramos-Remus, J. Rovensky, E. Alecock, T. Woodworth, and R. Alten; OPTION Investigators. 2008. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371: 987-997.
3. Baslund, B., N. Tvede, B. Danneskiold-Samsoe, P. Larsson, G. Panayi, J. Petersen, L. J. Petersen, F. J. Beurskens, J. Schuurman, J. G. van de Winkel, et al. 2005. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum. 52: 2686-2692.
4. Sloan-Lancaster, J., M. C. Genovese, S. A. Roberson, and F. Van den Bosch. 2009. Safety, tolerability, and evidence of efficacy of intravenous ly2439821 in patients with rheumatoid arthritis receiving background oral DMARDs. Ann. Rheum. Dis. 68: 125.
5. Ghoreschi, K., A. Laurence, and J. J. O'Shea. 2009. Janus kinases in immune cell signaling. Immunol. Rev. 228: 273-287.
6. Pesu, M., A. Laurence, N. Kishore, S. H. Zwillich, G. Chan, and J. J. O'Shea. 2008. Therapeutic targeting of Janus kinases. Immunol. Rev. 223: 132-142.
7. Ihle, J. N. 1995. The Janus protein tyrosine kinases in hematopoietic cytokine signaling. Semin. Immunol. 7: 247-254.
8. O'Shea, J. J., M. Pesu, D. C. Borie, and P. S. Changelian. 2004. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat. Rev. Drug Discov. 3: 555-564.
9. Changelian, P. S., M. E. Flanagan, D. J. Ball, C. R. Kent, K. S. Magnuson, W. H. Martin, B. J. Rizzuti, P. S. Sawyer, B. D. Perry, W. H. Brissette, et al. 2003. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302: 875-878.
10. Williams, N. K., R. S. Bamert, O. Patel, C. Wang, P. M. Walden, A. F. Wilks, E. Fantino, J. Rossjohn, and I. S. Lucet. 2009. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J. Mol. Biol. 387: 219-232.
11. Jiang, J. K., K. Ghoreschi, F. Deflorian, Z. Chen, M. Perreira, M. Pesu, J. Smith, D. T. Nguyen, E. H. Liu, W. Leister, et al. 2008. Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl- 3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl) -3-oxopropanenitrile (CP-690,550). J. Med. Chem. 51: 8012-8018.
12. Guschin, D., N. Rogers, J. Briscoe, B. Witthuhn, D. Watling, F. Horn, S. Pellegrini, K. Yasukawa, P. Heinrich, G. R. Stark, et al. 1995. A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. EMBO J. 14: 1421-1429.
13. Ellingsen, T., A. Buus, and K. Stengaard-Pedersen. 2001. Plasma monocyte chemoattractant protein 1 is a marker for joint inflammation in rheumatoid arthritis. J. Rheumatol. 28: 41-46.
14. Brand, D. D., K. A. Latham, and E. F. Rosloniec. 2007. Collagen-induced arthritis. Nat. Protoc. 2: 1269-1275.
15. Khachigian, L. M. 2006. Collagen antibody-induced arthritis. Nat. Protoc. 1: 2512-2516.
16. Brodmerkel, C. M., R. Huber, M. Covington, S. Diamond, L. Hall, R. Collins, L. Leffet, K. Gallagher, P. Feldman, P. Collier, et al. 2005. Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. J. Immunol. 175: 5370-5378.
17. Fridman, J., P. Scherle, R. Collins, T. Burn, Y. Li, J. Li, M. Covington, B. Thomas, M. Favata, J. Shi, et al. 2008. Preclinical characterization of INCB028050, JAK1/JAK2 selective clinical candidate. Arthritis Rheum. 58: S296.
18. Lacronique, V., A. Boureux, R. Monni, S. Dumon, M. Mauchauffé, P. Mayeux, F. Gouilleux, R. Berger, S. Gisselbrecht, J. Ghysdael, and O. A. Bernard. 2000. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood 95: 2076-2083.
19. Milici, A. J., E. M. Kudlacz, L. Audoly, S. Zwillich, and P. Changelian. 2008. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res. Ther. 10: R14.
20. Young, D. A., M. Hegen, H. L. Ma, M. J. Whitters, L. M. Albert, L. Lowe, M. Senices, P. W. Wu, B. Sibley, Y. Leathurby, et al. 2007. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum. 56: 1152-1163.
21. Diveu, C., M. J. McGeachy, and D. J. Cua. 2008. Cytokines that regulate autoimmunity. Curr. Opin. Immunol. 20: 663-668.
22. Parham, C., M. Chirica, J. Timans, E. Vaisberg, M. Travis, J. Cheung, S. Pflanz, R. Zhang, K. P. Singh, F. Vega, et al. 2002. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168: 5699-5708.
23. Alonzi, T., E. Fattori, D. Lazzaro, P. Costa, L. Probert, G. Kollias, F. De Benedetti, V. Poli, and G. Ciliberto. 1998. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187: 461-468.
24. Lubberts, E., M. I. Koenders, B. Oppers-Walgreen, L. van den Bersselaar, C. J. Coenen-de Roo, L. A. Joosten, and W. B. van den Berg. 2004. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 50: 650-659.
25. Murphy, C. A., C. L. Langrish, Y. Chen, W. Blumenschein, T. McClanahan, R. A. Kastelein, J. D. Sedgwick, and D. J. Cua. 2003. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198: 1951-1957.
26. Nakae, S., A. Nambu, K. Sudo, and Y. Iwakura. 2003. Suppressionof immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 171: 6173-6177.
27. Takagi, N., M. Mihara, Y. Moriya, N. Nishimoto, K. Yoshizaki, T. Kishimoto, Y. Takeda, and Y. Ohsugi. 1998. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. 41: 2117-2121.
28. Price, K. 2008. Cellular immune response in delayed-type hypersensitivity tests. In Immunotoxicology Strategies for Pharmaceutical Saftey Assessment. D. J. Herzyk and J. L. Bussiere, ed. John Wiley & Sons, Hoboken, NJ, p. 87.
29. Neubauer, H., A. Cumano, M. Müller, H. Wu, U. Huffstadt, and K. Pfeffer. 1998. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93: 397-409.
30. Parganas, E., D. Wang, D. Stravopodis, D. J. Topham, J. C. Marine, S. Teglund, E. F. Vanin, S. Bodner, O. R. Colamonici, J. M. van Deursen, et al. 1998. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93: 385-395.
31. Bush, K. A., K. M. Farmer, J. S. Walker, and B. W. Kirkham. 2002. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum. 46: 802-805.
32. Kagari, T., H. Doi, and T. Shimozato. 2002. The importance of IL-1 beta and TNF-alpha, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J. Immunol. 169: 1459-1466.
33. Williams, W., P. Scherle, J. Shi, R. Newton, E. McKeever, J. Fridman, T. Burn, K. Vaddi, R. Levy, and L. Moreland. 2008. A randomized placebo-controlled study of INCB018424, a selective janus kinase1&2 (JAK1&2) inhibitor in rheumatoid arthritis (RA). Arthritis Rheum. 58: S431.
34. Verstovsek, S., H. Kantarjian, A. Pardanani, D. Thomas, J. Cortes, R. Mesa, J. Redman, C. M. Staschen, J. Fridman, K. Vaddi, and A. Tefferi. 2007. INCB018424, an oral, selective JAK2 inhibitor, shows significant clinical activity in a phase i/ii study in patients with primary myelofibrosis (PMF) and post polycythemia ver/essential thrombocythemia myelofibrosis (Post-PV/ET MF). In ASH Annual Meeting 110: 171a.